South Korea
· Delayed Price · Currency is KRW ORIENT BIO Statistics
Total Valuation
ORIENT BIO has a market cap or net worth of KRW 55.13 billion.
| Market Cap | 55.13B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
ORIENT BIO has 118.57 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 118.57M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.00% |
| Owned by Insiders (%) | 3.53% |
| Owned by Institutions (%) | 0.02% |
| Float | 76.35M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.93 |
| PB Ratio | 1.04 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 5.91 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.20.
| Current Ratio | 1.80 |
| Quick Ratio | 1.11 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 7.96 |
| Debt / FCF | 1.14 |
| Interest Coverage | -5.14 |
Financial Efficiency
Return on equity (ROE) is -12.42% and return on invested capital (ROIC) is -2.75%.
| Return on Equity (ROE) | -12.42% |
| Return on Assets (ROA) | -2.20% |
| Return on Capital (ROIC) | -2.75% |
| Revenue Per Employee | 472.73M |
| Profits Per Employee | -54.83M |
| Employee Count | 125 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 5.30 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.71% in the last 52 weeks. The beta is 0.92, so ORIENT BIO's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | -31.71% |
| 50-Day Moving Average | 460.38 |
| 200-Day Moving Average | 520.07 |
| Relative Strength Index (RSI) | 53.70 |
| Average Volume (20 Days) | 140,632 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ORIENT BIO had revenue of KRW 59.09 billion and -6.85 billion in losses. Loss per share was -57.81.
| Revenue | 59.09B |
| Gross Profit | 21.25B |
| Operating Income | -2.87B |
| Pretax Income | -6.68B |
| Net Income | -6.85B |
| EBITDA | 1.34B |
| EBIT | -2.87B |
| Loss Per Share | -57.81 |
Balance Sheet
The company has 12.40 billion in cash and 10.66 billion in debt, giving a net cash position of 1.74 billion or 14.69 per share.
| Cash & Cash Equivalents | 12.40B |
| Total Debt | 10.66B |
| Net Cash | 1.74B |
| Net Cash Per Share | 14.69 |
| Equity (Book Value) | 52.82B |
| Book Value Per Share | 445.52 |
| Working Capital | 17.71B |
Cash Flow
In the last 12 months, operating cash flow was 11.74 billion and capital expenditures -2.41 billion, giving a free cash flow of 9.33 billion.
| Operating Cash Flow | 11.74B |
| Capital Expenditures | -2.41B |
| Free Cash Flow | 9.33B |
| FCF Per Share | 78.69 |
Margins
Gross margin is 35.96%, with operating and profit margins of -4.86% and -11.60%.
| Gross Margin | 35.96% |
| Operating Margin | -4.86% |
| Pretax Margin | -11.30% |
| Profit Margin | -11.60% |
| EBITDA Margin | 2.27% |
| EBIT Margin | -4.86% |
| FCF Margin | 15.79% |
Dividends & Yields
ORIENT BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.36% |
| Shareholder Yield | -8.36% |
| Earnings Yield | -12.43% |
| FCF Yield | 16.92% |
Stock Splits
The last stock split was on February 5, 2020. It was a reverse split with a ratio of 0.445400571.
| Last Split Date | Feb 5, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.445400571 |
Scores
ORIENT BIO has an Altman Z-Score of 4.22.
| Altman Z-Score | 4.22 |
| Piotroski F-Score | n/a |